^
Association details:
| Biomarker: | EGFR T790M + EGFR C797S |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | gefitinib (EGFR inhibitor) + Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma
Published date:
06/24/2021
Excerpt:
A 43-year-old male Asian non-smoker underwent surgical resection of lung mass...right remained adenocarcinoma harboring EGFR T790M and cis-C797S mutation...The patient sequentially received etoposide and cisplatin, anlotinib plus gefitinib...Finally, he died after one cycle of etoposide and carboplatin plus durvalumab treatment in March 2020.
Secondary therapy:
cisplatin + etoposide IV
DOI:
10.3389/fonc.2021.661034
